Luteolin Attenuates Hepatic Steatosis and Insulin Resistance Through the Interplay Between the Liver and Adipose Tissue in Mice with Diet-Induced Obesity

Diabetes - Tập 64 Số 5 - Trang 1658-1669 - 2015
Eun-Young Kwon1, Un Ju Jung1, Taesun Park2, Jong Won Yun3, Myung-Sook Choi1
11Center for Food and Nutritional Genomics Research, Kyungpook National University, Daegu, Republic of Korea
22Department of Food and Nutrition, Yonsei University, Seoul, Republic of Korea
33Department of Biotechnology, Daegu University, Kyungsan, Kyungbuk, Republic of Korea

Tóm tắt

The flavonoid luteolin has various pharmacological activities. However, few studies exist on the in vivo mechanism underlying the actions of luteolin in hepatic steatosis and obesity. The aim of the current study was to elucidate the action of luteolin on obesity and its comorbidity by analyzing its transcriptional and metabolic responses, in particular the luteolin-mediated cross-talk between liver and adipose tissue in diet-induced obese mice. C57BL/6J mice were fed a normal, high-fat, and high-fat + 0.005% (weight for weight) luteolin diet for 16 weeks. In high fat–fed mice, luteolin improved hepatic steatosis by suppressing hepatic lipogenesis and lipid absorption. In adipose tissue, luteolin increased PPARγ protein expression to attenuate hepatic lipotoxicity, which may be linked to the improvement in circulating fatty acid (FA) levels by enhancing FA uptake genes and lipogenic genes and proteins in adipose tissue. Interestingly, luteolin also upregulated the expression of genes controlling lipolysis and the tricarboxylic acid (TCA) cycle prior to lipid droplet formation, thereby reducing adiposity. Moreover, luteolin improved hepatic insulin sensitivity by suppressing SREBP1 expression that modulates Irs2 expression through its negative feedback and gluconeogenesis. Luteolin ameliorates the deleterious effects of diet-induced obesity and its comorbidity via the interplay between liver and adipose tissue.

Từ khóa


Tài liệu tham khảo

Knobler, 1999, Fatty liver—an additional and treatable feature of the insulin resistance syndrome, QJM, 92, 73, 10.1093/qjmed/92.2.73

Bugianesi, 2005, Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity, J Clin Endocrinol Metab, 90, 3498, 10.1210/jc.2004-2240

Greenberg, 2006, Obesity and the role of adipose tissue in inflammation and metabolism, Am J Clin Nutr, 83, 461S, 10.1093/ajcn/83.2.461S

Kabir, 2005, Molecular evidence supporting the portal theory: a causative link between visceral adiposity and hepatic insulin resistance, Am J Physiol Endocrinol Metab, 288, E454, 10.1152/ajpendo.00203.2004

Lomonaco, 2012, Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease, Hepatology, 55, 1389, 10.1002/hep.25539

Kim, 2003, Luteolin inhibits the nuclear factor-κ B transcriptional activity in Rat-1 fibroblasts, Biochem Pharmacol, 66, 955, 10.1016/S0006-2952(03)00465-9

Lim, 2007, Induction of cell cycle arrest and apoptosis in HT-29 human colon cancer cells by the dietary compound luteolin, Am J Physiol Gastrointest Liver Physiol, 292, G66, 10.1152/ajpgi.00248.2006

Zhou, 2008, Intestinal absorption of luteolin from peanut hull extract is more efficient than that from individual pure luteolin, J Agric Food Chem, 56, 296, 10.1021/jf072612+

Jang, 2010, Luteolin inhibits microglia and alters hippocampal-dependent spatial working memory in aged mice, J Nutr, 140, 1892, 10.3945/jn.110.123273

Lee, 2012, Luteolin exerts anti-tumor activity through the suppression of epidermal growth factor receptor-mediated pathway in MDA-MB-231 ER-negative breast cancer cells, Food Chem Toxicol, 50, 4136, 10.1016/j.fct.2012.08.025

Kang, 2011, Luteolin ameliorates cisplatin-induced acute kidney injury in mice by regulation of p53-dependent renal tubular apoptosis, Nephrol Dial Transplant, 26, 814, 10.1093/ndt/gfq528

Kim, 2011, The effects of luteolin on osteoclast differentiation, function in vitro and ovariectomy-induced bone loss, J Nutr Biochem, 22, 8, 10.1016/j.jnutbio.2009.11.002

Folch, 1957, A simple method for the isolation and purification of total lipides from animal tissues, J Biol Chem, 226, 497, 10.1016/S0021-9258(18)64849-5

Shao, 1997, Coincubation of rat renal proximal tubules with hepatic subcellular fractions potentiates the effects of para-aminophenol, Fundam Appl Toxicol, 39, 101, 10.1006/faat.1997.2364

Rudack, 1971, Rat liver glucose 6-phosphate dehydrogenase. Regulation by carbohydrate diet and insulin, J Biol Chem, 246, 1249, 10.1016/S0021-9258(19)76965-8

Lazarow, 1981, Assay of peroxisomal beta-oxidation of fatty acids, Methods Enzymol, 72, 315, 10.1016/S0076-6879(81)72021-4

Walton, 1985, Mg2-dependent phosphatidate phosphohydrolase of rat lung: development of an assay employing a defined chemical substrate which reflects the phosphohydrolase activity measured using membrane-bound substrate, Anal Biochem, 151, 479, 10.1016/0003-2697(85)90208-8

Shapiro, 1974, Micro assay for 3-hydroxy-3-methylglutaryl-CoA reductase in rat liver and in L-cell fibroblasts, Biochim Biophys Acta, 370, 369, 10.1016/0005-2744(74)90098-9

Gillies, 1986, Regulation of acyl-CoA:cholesterol acyltransferase activity in normal and atherosclerotic rabbit aortas: role of a cholesterol substrate pool, Exp Mol Pathol, 44, 329, 10.1016/0014-4800(86)90046-8

Alegre, 1988, Determination of glucose-6-phosphatase activity using the glucose dehydrogenase-coupled reaction, Anal Biochem, 173, 185, 10.1016/0003-2697(88)90176-5

Davidson, 1987, Factors underlying significant underestimations of glucokinase activity in crude liver extracts: physiological implications of higher cellular activity, Arch Biochem Biophys, 253, 156, 10.1016/0003-9861(87)90648-5

Bentle, 1976, Interaction of anions and divalent metal ions with phosphoenolpyruvate carboxykinase, J Biol Chem, 251, 2916, 10.1016/S0021-9258(17)33478-6

Seifter, 1950, The estimation of glycogen with the anthrone reagent, Arch Biochem, 25, 191

Wolff, 1994, Ferrous ion oxidation in presence of ferric ion indicator xylenol orange for measurement of hydroperoxides, Methods Enzymol, 233, 182, 10.1016/S0076-6879(94)33021-2

Do, 2010, Hepatic transcription response to high-fat treatment in mice: microarray comparison of individual vs. pooled RNA samples, Biotechnol J, 5, 970, 10.1002/biot.201000046

Schmittgen, 2008, Analyzing real-time PCR data by the comparative C(T) method, Nat Protoc, 3, 1101, 10.1038/nprot.2008.73

Park, 2013, Modulation of lipid metabolism by polyphenol-rich grape skin extract improves liver steatosis and adiposity in high fat fed mice, Mol Nutr Food Res, 57, 360, 10.1002/mnfr.201200447

Zhou, 2012, Cidea promotes hepatic steatosis by sensing dietary fatty acids, Hepatology, 56, 95, 10.1002/hep.25611

Heid, 1998, Adipophilin is a specific marker of lipid accumulation in diverse cell types and diseases, Cell Tissue Res, 294, 309, 10.1007/s004410051181

Chen, 2008, ApoB100 is required for increased VLDL-triglyceride secretion by microsomal triglyceride transfer protein in ob/ob mice, J Lipid Res, 49, 2013, 10.1194/jlr.M800240-JLR200

Huff, 1994, Inhibition of hepatic ACAT decreases ApoB secretion in miniature pigs fed a cholesterol-free diet, Arterioscler Thromb, 14, 1498, 10.1161/01.ATV.14.9.1498

Wu, 2010, PPARgamma is essential for protection against nonalcoholic steatohepatitis, Gene Ther, 17, 790, 10.1038/gt.2010.41

Valverde, 2003, Molecular mechanisms of insulin resistance in IRS-2-deficient hepatocytes, Diabetes, 52, 2239, 10.2337/diabetes.52.9.2239

Walker, 2011, A conserved SREBP-1/phosphatidylcholine feedback circuit regulates lipogenesis in metazoans, Cell, 147, 840, 10.1016/j.cell.2011.09.045

Tsunekawa, 2011, FoxO feedback control of basal IRS-2 expression in pancreatic β-cells is distinct from that in hepatocytes, Diabetes, 60, 2883, 10.2337/db11-0340